ArticleCureus2026
Human Insulin-Like Growth Factor II mRNA-Binding Protein 3 (IMP3) and p16 Expression in Squamous Cell Carcinoma of the Head and Neck.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Head and neck squamous cell carcinoma (HNSCC) represents a substantial global health problem due to its considerable incidence and frequent presentation at advanced stages. The validation of biomarkers is essential to facilitate early detection and prognosis and inform targeted therapeutic interventions which can contribute to improved clinical outcomes. This study investigates the immunohistochemical expression patterns of two promising biomarkers: the oncofetal protein human insulin-like growth factor II mRNA-binding protein 3 (IMP3) and the tumour suppressor p16. IMP3, normally expressed during embryogenesis, is aberrantly re-expressed in malignancies and linked to tumour progression and poor outcomes. Conversely, p16 overexpression is frequently linked to human papillomavirus (HPV)-related carcinogenesis and is considered a favorable prognostic marker in HNSCC. Materials and methods A cross-sectional study of 50 HNSCC cases over 18 months evaluated IMP3 and p16 expression and correlated findings with clinicopathological variables (demographics, site, grade, stage, tobacco/alcohol use). Immunohistochemistry followed standard protocols with appropriate positive and negative controls. Statistical analyses used the chi-squared and Fisher's exact tests where applicable. Results and conclusions IMP3 was positive in 27 (54%) and p16 in six (12%) of HNSCC cases. The markers were mutually exclusive and showed significant associations with gender and tobacco use. IMP3 expression was higher in males (p < 0.05), while p16 correlated with specific risk factors, consistent with HPV-related pathways. Their mutual exclusivity suggests distinct molecular mechanisms in HNSCC. These differential patterns support IMP3 and p16 as complementary biomarkers for patient stratification and tailored management strategies. Further studies integrating molecular HPV status and long-term follow-up are needed to validate prognostic and therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.